Official Program - March 14-15

Thursday March 14

7:30 - 8:50

Registration – Hall –  2nd floor
Breakfast – Pall Mall, Palm Court and Vanity Fair Ballroom B

8:50 - 9:00

Welcome from CellCAN – Regenerative Medicine and Cell Therapy Network

Denis Claude Roy, CEO, CellCAN

Vanity Fair Ballroom A

9:00 - 9:20

The patient to patient interview: a life changing therapy

Moderator: William Brock, Survivor of acute myelogenous leukemia (AML), CellCAN Chairman of the Board
Patient: Mai Duong, Survivor of leukemia, Founder, Swab the World

Vanity Fair Ballroom A

Theme 1: Innovation in allogeneic cellular therapies: game changer in regenerative medicine

Moderator: Michel Rochon, Health and Science Journalist 

Chair: Heidi Elmoazzen, Director, Stem Cells, Canadian Blood Services

 

 Vanity Fair Ballroom A

9:20 - 10:20

Engineering stem cells for islet cell replacement
Tim Kieffer, Professor, Cellular & Physiological Sciences and Surgery, University of British Columbia

Generating a FailSafeTM kill switch for allogeneic cellular therapies
Andras Nagy, Canada Research Chair in Stem Cells and Regeneration, Senior Scientific Investigator, Lunenfeld-Tanenbaum Research Institute, Sinai Health System

10:20 - 10:40

Health break and exhibitors visit

10:40 - 12:00

Preparing for first human trial of iPSC-derived cells for Parkinson’s disease
Daisuke Doi, Research associate, Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Japan

Panelist discussion: Allogeneic vs autologous sourced donor cells: the strategic advantages

  • Duncan Stewart, President, OHRI, CEO, OIRM
  • Lucie Germain, Professor Université Laval, CHU de Québec-Université Laval
  • Andras Nagy, Canada Research Chair in Stem Cells and Regeneration, Senior Scientific Investigator, Lunenfeld-Tanenbaum Research Institute, Sinai Health System
  • Daisuke Doi, Research associate, Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Japan  

12:00 -14:00

Lunch, networking and exhibitors visit

Pall Mall, Palm Court and Vanity Fair Ballroom B

14:00 - 14:15

The patient to patient interview: a life changing therapy

Moderator: William Brock, Survivor of AML, CellCAN Chairman of the Board
Patient: Kevin Bolusi, Self-Assembling Skin Substitute recipient, Survivor of 3rd degree burns

Special guests:
Lucie Germain, Professor, Université Laval, CHU de Québec-Université Laval
Véronique Moulin, Researcher, LOEX, CHU de Québec Research Center-Université Laval

Vanity Fair Ballroom A

Theme 2: The next generation of clinical trials

Moderator: Michel Rochon, Health and Science Journalist 

Chair: Janet Dancey, Director, Canadian Cancer Trials Group, Scientific Director, Canadian Cancer Clinical Trials Network, Professor, Department of Oncology, Queen's University

Vanity Fair Ballroom A

14:15 - 15:15

Gene therapy studies for thalassemia and sickle cell anemia
Donna Wall, Blood and Marrow Transplant/Cellular Therapy Program, The Hospital for Sick Children/University of Toronto 

Canadian manufacturing and delivery of CAR-T therapy as health care implementation research
Rob Holt, Co-Director and Distinguished Scientist, BC Cancer Immunotherapy Program, BC Cancer Genome Sciences Centre

15:15 - 15:45

Health break and exhibitors visit

15:45 - 16:45

Taking CAR-T from theory to reality - the Novartis experience
Marta Majdan, Medical Advisor, Oncology, Novartis Canada

Panel discussion: Vision of clinical trials for the next 5-10 years

  • Denis Claude Roy, CEO, CellCAN
  • Donna Wall, Blood and Marrow Transplant/Cellular Therapy Program, The Hospital for Sick Children/University of Toronto
  • Marta Majdan, Medical Advisor, Oncology, Novartis Canada

16:45 - 17:00

Wrap-up of day 1

Denis Claude Roy, CEO, CellCAN
Armand Keating, Director, Cell Therapy Program, University Health Network

18:00 - 21:00

Industry Networking Event (sponsored by STEMCELL Technologies)

Vanity Fair Foyer, Palm Mall and Palm Court


Friday March 15

7:00- 8:00

Registration – Hall  

Breakfast – Pall Mall, Palm Court and Vanity Fair Ballroom B

8:00 - 8:05

Introduction to day 2 activities
Denis Claude Roy, CEO, CellCAN

Vanity Fair Ballroom A

8:05 - 8:35

NRC Health Challenge Program: Initiatives & collaboration models to improve affordability and accessibility of cell and gene therapies in Canada
Bernard Massie,
 Director General (acting), Human Health Therapeutics Research Centre, National Research Council of Canada

Vanity Fair Ballroom A

Theme 3:  Regulatory Reform and Reimbursement

Moderator: Michel Rochon, Health and Science Journalist 

Chair: Sowmya Viswanathan, University Health Network

Vanity Fair Ballroom A

8:35 - 9:35

Regulatory reform in Canada: modernizing novel cell & gene therapy regulations
Pierre Sabourin
, Assistant Deputy Minister, Health Products and Food Branch, Health Canada
represented by Celia Lourenco, Director General, Biologics and Genetic Therapies Directorate (BGTD), Health Products and Food Branch, Health Canada 

Drug review process alignment: Health Canada, CADTH & INESSS collaboration
Alexandra Chambers
, Director of the pan-Canadian Oncology Drug Review (pCODR) program, CADTH

9:35 - 10:00 Health break and exhibitors visit

10:00 - 12:00 

Redefining outcome measures for efficacy and novel clinical trial design in gene therapy treatments - A value demonstration approach
Kathy Reape, Chief Medical Officer, Spark Therapeutics

Challenges of implementing new technologies in the healthcare system
Lambert Busque, Hematologist, Hôpital Maisonneuve-Rosemont, Chief Medical Officer, C3i

Panel Discussion – Regulatory & Reimbursement in Canada’s public payer system: is there value in regenerative medicine technologies?

  • Lesley Dunfield, Director of HTA and Program Development for Medical Devices and Clinical Interventions portfolio, CADTH
  • Siofradh McMahon, Senior Manager, Clinical Translation and Regulatory Affairs, CCRM
  • Michèle de Guise, Directrice des services de santé et de l'évaluation des technologies, INESSS
  • Lambert Busque, Hematologist, Hôpital Maisonneuve-Rosemont, Chief Medical Officer, C3i

12:00 - 14:00

Lunch, networking and exhibitors visit

Pall Mall, Palm Court and Vanity Fair Ballroom B

14:00 - 14:15

The patient to patient interview: a life changing therapy

Moderator: William Brock, Survivor of AML, CellCAN Chairman of the Board
Patient: Marc Doucett, Survivor of multiple sclerosis

Vanity Fair Ballroom A

Theme 4: Optimizing cell and gene therapy manufacturing

Moderator: Michel Rochon, Health and Science Journalist 

Chair: Michael May, CEO, CCRM

Vanity Fair Ballroom A

14:15 - 15:45

3D printing human tissue: where engineering meets biology
Spiro Getsios, VP of Tissue Engineering, Aspect Biosystems

Scale-up, cost reduction and data considerations for cell manufacturing
Gary Pigeau
, Director, Centre for Advanced Therapeutic Cell Technologies at CCRM, GE Healthcare

Planning for Success - the path to commercialization
Donna Rill
, Chief Technology Officer, Triumvira

15:45 - 16:15

Health break and exhibitors visit

16:15 - 17:15

Panelist Discussion: Centralized vs. decentralized manufacturing - opportunities & challenges

  • Behnam Baghbadernai, Global Head, Process Development & Emerging Technologies - Cell & Gene Therapy, Lonza 
  • Robert Preti, CEO and President, Hitachi Chemical Advanced Therapeutics Solutions
  • Mayo Pujols, VP and Global Head of Cell & Gene Technical Development & Manufacturing, Novartis
  • Nuala Trainor, Director of Biologics, Octane 

17:15 - 17:30

Closing remarks 

Denis Claude Roy, CEO, CellCAN